3D Signatures Inc.

3D Signatures Inc. is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of a patient's individual chromosomal arrangement − or signature. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease. Depending on the application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient.

Expert Comments:

One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company, which is at the forefront of using three-dimensional telomere analysis to personalize medical treatment.
read more >
BioTuesdays Publishing Co. (4/4/17)
"3D Signatures Inc. successfully completing internal analytical assay validation for its Hodgkin's Lymphoma test."

Magdalena Kegel, Alzheimer's News Today (3/22/17)
"3D Signatures Inc. has developed a simple cheek swab to identify patients with Alzheimer's disease, and even distinguish among those with mild, moderate or severe stages of the illness, according to results from a clinical trial. . .the search for sensitive and non-invasive markers to detect Alzheimerís has been a hot topic lately. For now, scientists can only make a definitive diagnosis of Alzheimerís after death, and amyloid plaques are detected in a patientís brain. . .the software was able to correctly pick those with Alzheimer's."

Etienne Moshevich, Alphastox.com (3/2/17)
"I wanted to send out a quick update on 3D Signatures Inc. after two tremendous announcements last week that I believe the market totally missed, which is where we see a major buying opportunity. . . .3D has a disruptive platform technology and thereís no doubt in my mind that they have already caught the attention of major pharmaceutical companies. . .I see the prostate cancer and Hodgkinís lymphoma programs as a major step forward in terms of validating the investment opportunity and driving the value creation process. DXD is at a strong support level with lots of good news expected over the next 6-12 months."

Shane Matte, BioTuesdays (2/23/17)
"The validation program for 3D Signatures Inc.ís Hodgkin's lymphoma test (Telo-HL) is under way. Telo-HL is powered by the company's TeloView software platform. . .there is currently no biomarker available that can predict patient response to standard chemotherapy in HL patients, and thereby help guide treatment decisions on an individual basis. . .the ability to identify the appropriate treatment for an individual patient at the time of diagnosis should result in expedited use of alternative treatment options and cost savings to the payer."

More Expert Comments

Experts Following This Company

Shane Matte BioTuesdays
Etienne Moshevich, Editor Alphastox.com

The information provided above is from analysts, newsletters, the company and other contributors.

3D Signatures Inc. is a sponsor of Streetwise Reports.†The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
Disruptive Technology
Software as a Service (SaaS) Business Model
Attracting Industry Majors